Donor age-related differences in PBPC mobilization with rHuG-CSF

被引:46
作者
de la Rubia, J [1 ]
Díaz, MA [1 ]
Verdeguer, A [1 ]
Pascual, MJ [1 ]
Arbona, C [1 ]
Arrieta, R [1 ]
Brunet, S [1 ]
Bargay, J [1 ]
Martínez, C [1 ]
Espigado, I [1 ]
Serrano, D [1 ]
Alegre, A [1 ]
de Arriba, F [1 ]
de la Serna, J [1 ]
Zamora, C [1 ]
Benlloch, L [1 ]
Sanz, MA [1 ]
机构
[1] La Fe Hosp, Spanish Grp Allogen Peripheral Blood Stem Cell Tr, Valencia, Spain
关键词
D O I
10.1046/j.1537-2995.2001.41020201.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Data on the administration of rHuG-CSF to normal donors <18 years old are very limited. STUDY DESIGN AND METHODS: The results of rHuG-CSF administration to 61 donors <18 years old (Group A) were retrospectively evaluated and compared with results from 353 donors greater than or equal to 18 years old (Group B) who are included; in the Spanish National Donor Registry. The mean age(range) in Group A and B was 14 (1-17) and 38 (18-71)years, respectively (p<0.001). The mean dose of rHuG-CSF was 10 <mu>g per kg per day (range, 9-16) during a mean of 5 days (range, 4-6). Central venous access was placed more frequently in younger donors (25% vs. 6%; p<0.001). RESULTS: The mean number of CD34+ cells collected was 7.6 and 6.9 x 10(6) per kg of donor's body weight in Group A and B, respectively. Fifty-six percent of Group A donors needed only one apheresis to achieve 14 x 10(6) CD34+ cells per kg versus 39 percent of Group B donors (p = 0.01). Side effects were more common in Group B (71% vs. 41%; p<0.001). CONCLUSION:The administration of rHuG-CSF to donors <18 years old leads to CD34+ cell mobilization in a pattern similar to that observed in adults. Greater age was associated with a more frequent requirement for more than one apheresis to achieve a similar number of CD34+ cells.
引用
收藏
页码:201 / 205
页数:5
相关论文
共 23 条
[1]   Factors affecting mobilization of CD34+ cells in normal donors treated with filgrastim [J].
Anderlini, P ;
Przepiorka, D ;
Seong, C ;
Smith, TL ;
Huh, YO ;
Lauppe, J ;
Champlin, R ;
Korbling, M .
TRANSFUSION, 1997, 37 (05) :507-512
[2]  
Anderlini P, 1997, BLOOD, V90, P903
[3]   Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures [J].
Anderlini, P ;
Przepiorka, D ;
Seong, D ;
Miller, P ;
Sundberg, J ;
Lichtiger, B ;
Norfleet, F ;
Chan, KW ;
Champlin, R ;
Korbling, M .
TRANSFUSION, 1996, 36 (07) :590-595
[4]   Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim:: the M.D. Anderson Cancer Center experience [J].
Anderlini, P ;
Donato, M ;
Chan, KW ;
Huh, YO ;
Gee, AP ;
Lauppe, MJ ;
Champlin, RE ;
Körbling, M .
TRANSFUSION, 1999, 39 (06) :555-560
[5]  
BUCKNER CD, 1984, BLOOD, V64, P630
[6]  
CHATTA GS, 1994, BLOOD, V84, P2923
[7]   Administration of recombinant human granulocyte colony-stimulating factor to normal donors:: results of the Spanish National Donor Registry [J].
de la Rubia, J ;
Martínez, C ;
Solano, C ;
Brunet, S ;
Cascón, P ;
Arrieta, R ;
Alegre, A ;
Bargay, J ;
de Arriba, F ;
Cañizo, C ;
López, J ;
Serrano, D ;
Verdeguer, A ;
Torrabadella, M ;
Díaz, MA ;
Insunza, A ;
de la Serna, J ;
Espigado, I ;
Petit, J ;
Martínez, M ;
Benlloch, L ;
Sanz, MA .
BONE MARROW TRANSPLANTATION, 1999, 24 (07) :723-728
[8]  
Dixon W. J., 1990, BMDP STAT SOFTWARE
[9]   G-CSF-MOBILIZED PERIPHERAL-BLOOD PROGENITOR CELLS FOR ALLOGENEIC TRANSPLANTATION - SAFETY, KINETICS OF MOBILIZATION, AND COMPOSITION OF THE GRAFT [J].
DREGER, P ;
HAFERLACH, T ;
ECKSTEIN, V ;
JACOBS, S ;
SUTTORP, M ;
LOFFLER, H ;
MULLERRUCHHOLTZ, W ;
SCHMITZ, N .
BRITISH JOURNAL OF HAEMATOLOGY, 1994, 87 (03) :609-613
[10]   Peripheral blood progenitor cell (PBPC) collection by large-volume leukapheresis from pediatric donors [J].
González, M ;
Benito, A ;
Diaz, MA ;
Madero, L .
BONE MARROW TRANSPLANTATION, 1999, 23 (06) :631-632